Dear AIB member
The Finance Accounting Research Unit (FARU) at the University of Hertfordshire (UK) in conjunction with the Institute for Chartered Accountants Scotland (ICAS) have issued a research report “UK bio-pharma: Innovation, re-invention and capital at risk”. This report on UK bio-pharma presents a strong case for emergency state funding where it can sensibly prevent a disorderly downsizing of bio-pharma and loss of intangible asset investment. In the medium and long-tem term, this report argues for active and imaginative Government policies that redraw the bio-pharma business model modifying the way in which risk and return are distributed between the different stakeholders involved in a complex and increasingly fragile business model.
This report can be downloaded from the ICAS website:http://www.icas.org.uk/site/cms/download/res/Gleadle_Haslam_Report_July_11.pdf